大和发表研究报告指,泰格医药(03347.HK) 的新订单与未完成订单的动力持续强劲,预期今年下半年高价订单的转化速度将会加快。管理层重申新签订单转化周期为6至9个月,在2026财年双位数收入增长指引下,该行预测其今年上半年及下半年收入分别达到约36亿及40亿元人民币。不过,该行提到,由于泰格医药在人工智能方面的投入增加,管理层将全年净利润指引下调约1亿元人民币(原本介乎6亿至7亿元人民币)。另外...
Source Link大和发表研究报告指,泰格医药(03347.HK) 的新订单与未完成订单的动力持续强劲,预期今年下半年高价订单的转化速度将会加快。管理层重申新签订单转化周期为6至9个月,在2026财年双位数收入增长指引下,该行预测其今年上半年及下半年收入分别达到约36亿及40亿元人民币。不过,该行提到,由于泰格医药在人工智能方面的投入增加,管理层将全年净利润指引下调约1亿元人民币(原本介乎6亿至7亿元人民币)。另外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.